

Critical Response to Article “Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer” [Letter]

Frans Dany , Uly Alfi Nikmah , Lisa Andriani Lienggonegoro 

Center for Biomedical Research, Health Research Organization, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia

Correspondence: Frans Dany, Center for Biomedical Research, Health Research Organization, National Research and Innovation Agency (BRIN), Genomic Building, Cibinong, Jl. Raya Bogor No. 490, Cibinong, West Java, 16911, Indonesia, Email fran012@brin.go.id; fransdany1@gmail.com

Dear editor

We reviewed the work by Zhao et al¹ about the potential therapy of Kanglaite from the perspective of in silico and in vitro studies. However, given numerous bioactive compounds in herbal medicine with their potential targets, interaction and effects, we noticed that critical points regarding methodology should be addressed properly.

First, the use of term “injection” in the title is quite misleading for readers since there was no Kanglaite administration via injection route in this study. Secondly, dosage standardization should be described in order to get an overview that the experiment had been conducted in reproducible manner.² Then, databases other than GEO, ie, DisGeNET should be included so that wider range of candidates for triple-negative breast cancer can be obtained.³ We tried to re-analyze the GEO dataset and found at least more than 1800 unique gene targets after normalization in GEO2R option (please see the [Supplementary File, Suppl 1.xlsx](#) in the sheet norm1 for the unique and normalized targets as well as the sheet not_norm1 for the non-normalized; the remaining sheets, sig_norm denotes the raw list of most significantly expressed genes retrieved from the Volcano Plot exploration window in GEO2R, Annotated_norm for target list with clear gene names and Duplicates_norm for the gene list with duplicate annotation. The sheet for the non-normalized counterparts was provided with the suffix _not_norm). Please note that the non-normalized ones yield higher numbers while in the paper, it is mentioned that 228 plus 53 overlapping targets were retrieved from GEO, making total of only 281 targets. Moreover, we note that around 1500 gene targets were found by using TNBC terms from DisGeNET only, as shown in the [Supplementary File, Suppl 1.xlsx](#) in sheet TNBC and TNBCa. Fourth, since this network involved many protein targets and multiple compounds, their interaction prediction could use such designated tools such as STITCH (<http://stitch.embl.de/>). Fifth, other centrality parameters such as betweenness and closeness should be included when building the network as these may contribute to different ranking of potential nodes.⁴

Lastly, the docking protocol should be validated with native ligand corresponding to its protein target as control and comparison is applied not only to their binding affinity, but also key residues implicated in their interaction at the same binding pocket.⁵ Since the results of this study are very promising, we hope that our suggestion can be considered in the future to optimize its findings.

Acknowledgments

We greatly thank Dr. Sunarno for his inputs during the writing of this manuscript.

Disclosure

All authors declare that they have no conflicts of interest in this communication.

References

1. Zhao M, Fu L, Xu P, Wang T, Li P. Network pharmacology and experimental validation to explore the effect and mechanism of kanglitaie injection against triple-negative breast cancer. *Drug Des Devel Ther.* 2023;17(March):901–917. doi:10.2147/DDDT.S397969
2. Leong F, Hua X, Wang M, et al. Quality standard of traditional Chinese medicines: comparison between European pharmacopoeia and Chinese pharmacopoeia and recent advances. *Chin Med.* 2020;15(1):1–20. doi:10.1186/s13020-020-00357-3
3. Deng Z, Chen G, Shi Y, et al. Curcumin and its nano-formulations: defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification. *Front Pharmacol.* 2022;13(August):1–16. doi:10.3389/fphar.2022.920514
4. Wang K, Li K, Chen Y, et al. Computational network pharmacology-based strategy to capture key functional components and decode the mechanism of Chai-Hu-Shu-Gan-San in treating depression. *Front Pharmacol.* 2021;12(November):1–17. doi:10.3389/fphar.2021.782060
5. Coumar MS. *Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications.* Academic Press; 2021. doi:10.1016/B978-0-12-822312-3.01001-8

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S417549>